Genentech -A PHASE III RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE COMPARATOR, MULTICENTER EVALUATION OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH nAMD
Research Grant
Awarded By
Genentech, Inc.
Start Date
December 20, 2018
End Date
August 1, 2022
Awarded By
Genentech, Inc.
Start Date
December 20, 2018
End Date
August 1, 2022